Gennex Laboratories share news, announcements and annual reports
BSE: 531739Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 29 Oct 2026. Previous close ₹9.10.
29 Oct: open ₹9.20, high ₹9.20, low ₹8.91
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹218 Cr2,248th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 11.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.98
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.15
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,88,622
Gennex Laboratories share news and announcements
553 announcements, routine notices left out, newest first. Page 4 of 12.
Jun 2023
15 Jun · Second And Final Reminder-Cum-Forfeiture Notice For First And Final Call Money And Of Gennex Laboratories Limited - BSE Security ID: GENNEX, Script Code: 531739 & 890171
13 Jun · Second And Final Reminder-Cum-Forfeiture Notice For First And Final Call Money And Of Gennex Laboratories Limited
8 Jun · Approval From APIIC - Industrial Area Local Authority On Name Change
1 Jun · Additional Details Regarding Time Of Commencement And Conclusion Of Board Meeting Of The Company Held On May 30, 2023;
1 Jun · License To Manufacture For Sale(Or For Distribution) Of Drugs Received Deccan Remedies Limited (Subsidiary Company) From Drug Control Administration Of Government Of Andhra Pradesh
May 2023
31 May · Approval From Pollution Control Board (PCB) On CFO Of Subsidiary (Deccan Remedies Limited)
30 May · Disclosure Under Regulation.23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015 Of Gennex Laboratories Limited
23 May · Board meeting
Meeting on 30 May 2023: audited results
Apr 2023
29 Apr · Compliance Certificate Under Regulation 7(2) & 7(3) Of The SEBI (LODR) Regulations, 2015 Of Gennex Laboratories Limited For The Half Year Ended March 31, 2023;
29 Apr · Compliance Certificate Under Regulation 40(9) & 40(10} Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 Of Gennex Laboratories Limited For The Half Year Ended March 31, Z023;
12 Apr · Board meeting
Meeting on 20 Apr 2023
Mar 2023
20 Mar · Approval From The Factories Department Of Andhra Pradesh For The Change In The Name Of Factory And Occupier In Favour Of Deccan Remedies Limited
2 Mar · Deccan Remedies Limited Acquired Pharma Unit Located JN Pharma City, Visakhapatnam
Feb 2023
7 Feb · Board meeting
Meeting on 14 Feb 2023: quarterly results
Jan 2023
10 Jan · 01St (First) Reminder For First And Final Call Money Notice
5 Jan · 01St (First) Reminder For First And Final Call Money Of Gennex Laboratories Limited
Nov 2022
25 Nov · Disclosure Pursuant To Regulation 23(9) Of The SEBI (LODR) Regulations, 2015 For The Half Year Ended September 30, 2022
4 Nov · Board meeting
Meeting on 14 Nov 2022: quarterly results
Oct 2022
28 Oct · Compliance Certificate Under Regulation 7(2) & 7(3) Of The SEBI (LODR) Regulations, 2015 For The Half Year Ended September 30, 2022
15 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 1 1 015 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 1 1 0
Sep 2022
28 Sep · Revision Of Call Money Payment Period Of First And Final Call